Observational studyJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine2025
Home sleep apnea testing in patients with continuous flow left ventricular assist device: is it feasible?
Observational study in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Home Sleep Apnoea Testing: Advances, Challenges and Considerations in Heart Failure.Cardiac failure review · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
objectivesThe incidence of sleep-related breathing disorder remains unclear in patients with a continuous flow left ventricular assist device. Polysomnography (PSG) remains the gold standard for diagnosis, but logistical challenges make home sleep apnea testing a more practical alternative. WatchPat has failed to accurately diagnose sleep-related breathing disorder in this population. In contrast, the NOX-T3 utilizes more channels to monitor physiological variables, potentially offering improved diagnostic accuracy. Therefore, we aimed to validate the NOX-T3 vs PSG in detecting sleep-related breathing disorder in patients with a durable left ventricular assist device.
methodsThis is a single-center, prospective, observational pilot study. Patients with left ventricular assist device who screened positive on the STOP-BANG Sleep Apnea Questionnaire were referred to sleep clinic. Patients recommended for PSG by a sleep physician underwent PSG and NOX-T3 simultaneously. Apnea-hypopnea index with the PSG and the respiratory event index using the NOX-T3 were compared as well as time spent with oxygen saturation ≤ 88% using Spearman's correlation.
resultsTen patients (8 males, 2 females) were enrolled. The average age was 54 ± 15 years and 9 were implanted with a HeartMate III device. There was a strong correlation between the apnea-hypopnea index obtained from NOX-T3 and PSG (
conclusionsOur results suggest that the NOX-T3 home sleep apnea testing device is a useful tool in the comprehensive evaluation of sleep-related breathing disorder in patients with left ventricular assist device. CITATION: Mutirangura P, Alexy T, Airhart SE, et al. Home sleep apnea testing in patients with continuous flow left ventricular assist device: is it feasible?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.